Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Net revenue:
Revenue		$ 113,243	$ 101,132	$ 330,962	$ 312,262
Cost of revenue:
Total cost of revenue	[1]	81,616	72,058	222,974	207,793
Gross profit		31,627	29,074	107,988	104,469
Operating expenses:
Research and development	[2]	10,712	10,909	36,472	40,203
Selling and marketing		9,110	10,318	31,906	31,923
General and administrative		10,758	12,409	36,005	38,656
Total operating expenses		30,580	33,636	104,383	110,782
Income (loss) from operations		1,047	(4,562)	3,605	(6,313)
Income from equity method investment, net		2,297	1,024	3,829	1,028
Interest expense		(2,890)	(2,884)	(8,728)	(8,728)
Other income (expense), net		(1,294)	524	357	(1,665)
Loss before provision for income taxes		(840)	(5,898)	(937)	(15,678)
Provision for income taxes		457	444	1,777	3,254
Net loss		$ (1,297)	$ (6,342)	$ (2,714)	$ (18,932)
Net loss per share - basic		$ (0.01)	$ (0.06)	$ (0.03)	$ (0.19)
Net loss per share - diluted		$ (0.01)	$ (0.06)	$ (0.03)	$ (0.19)
Weighted average common shares used in computing net loss per share:
Basic		102,825	99,197	101,462	97,838
Diluted		102,825	99,197	101,462	97,838
Other comprehensive loss:
Net Income (Loss)		$ (1,297)	$ (6,342)	$ (2,714)	$ (18,932)
Foreign currency translation adjustment		244	(2,965)	(935)	(2,330)
Comprehensive loss		(1,053)	(9,307)	(3,649)	(21,262)
Products
Net revenue:
Revenue	[3]	57,320	49,603	166,878	154,491
Cost of revenue:
Total cost of revenue		44,301	35,945	111,315	105,977
Services
Net revenue:
Revenue	[4]	55,923	51,529	164,084	157,771
Cost of revenue:
Total cost of revenue		$ 37,315	$ 36,113	$ 111,659	$ 101,816

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $17,411 and $53,303 during the three and nine months ended March 31, 2025, and $13,887 and $40,260 during the three and nine months ended March 31, 2024, respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $373 and $1,105 during the three and nine months ended March 31, 2025, and $199 during the nine months ended March 31, 2024. There were no charge backs to the joint venture related to research and development during the three months ended March 31, 2024.

[3] Includes sales of products to the joint venture, an equity method investment, of $17,967 and $76,333 during the three and nine months ended March 31, 2025, and $15,662 and $55,504 during the three and nine months ended March 31, 2024, respectively. See Note 12.

[4] Includes sales of services to the joint venture, an equity method investment, of $5,351 and $14,588 during the three and nine months ended March 31, 2025, and $3,982 and $10,970 during the three and nine months ended March 31, 2024, respectively. See Note 12.